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Psychosis in Alzheimer's Disease
George M. Strickland, M.D. 1 and
Thomas F. Ditzler, Ph.D.2
Abstract
Muchofthe basic scienceliterature on Alzheimer'sDisease (I ill) reflects ongoing research into
pathophysiology and neuropathology. Yet, despite reports qf the association between psychotic
symptoms and A lzheimer's disease, relatively little is known about why such symptoms develop in
certain patients and not in others. Neuroimaging and genetic studies lIlay provide greater
understanding ofthis association and allow clinicians and researchers toprevent, predict and treat
the onset ofpsychotic symptoms in thef uture. This paper will review the current literature on the
topic qfpsychosis in Alzh eimer's disease andfocus 0 11 current recommendationsfor interventions b)'
clinicians and caregivers.
METHODOLOGY
A lit erature search on th e Medl ine dat ab ase was performed . English la nguage
art icles publish ed between 1985-1 999 were cons idered. Keywords "Alzheim er's
Dis ea se", "de me ntia", "psychosis", and "ant i-psycho tics" were used in d iffer ent
combina tions . Referen ces in th ese a r t icles led to further referen ces ut ilized in th is
paper. Other sources include relevant textbook cita tions and recent journal art icles
fro m j ournal s not ava ilab le on the Medline dat ab ase.
INTRODUCTI O N
Alzh eimer's Disease (AD) repr esen ts the most common ca use of dementi a
accounting for about 80% of a ll cas es of dem en ti a ( I) . H istoricall y, AD was th e firs t
di sea se in whi ch mi croscopi c examina t ion of th e brai n revealed th e histopa th ologic
cha nges of se nile plaques, neurofibrillary tan gles, a nd gra nulovacuo lar degeneration
of neurons (2) . AD is a progr essive, irreversible dem entia that init iall y pr esents with
mem ory problems followed by lan gu age, mathem atical , visuos pat ia l, a nd person ality
decline ( I). The first sympto m is usu all y amnesia or the inability to learn new
information (I ). Langu age di fficulties begin wit h word-finding troubles followed by
IGeorge 1\1. Str ickland, M.D . is a four th year psych ia t ry resident a t Tripier Arm y Medical
Cent er, Honolulu, Hawaii.
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a nomia a nd a fluent aphas ia (I ). This corre la tes to th e neu rop a thology that is
greates t in th e region s posterior to W ernicke's a rea . Eventuall y th e patient becomes
mut e and ca nnot com pre he nd (I) . Visuo spatial deficit s and cog nit ion changes occur
whi ch corre la te to parietal and frontal injury (I). During th e end-stages of th e
di sease, th e patient is unable to swallow or mobilize a nd dea th oft en occurs
secondary to sepsis or deh ydration . This a r t icle will focus on psyc hot ic symptoms in
AD , but many othe r neuropsychi at ric features like persona lity changes, depression,
viole nce, slee p d isturban ce, a nd wa nde ring a re com mon ( I) .
AD causes profound emo tional suffe r ing a nd eco nom ic burden for patient s and
th ei r caregivers (3) . In 1997, th e pr eval en ce of AD in the US was 2.32 million with
a range of 1.09 to 4.58 million (4) . The lifetime risk of AD in the general population
is roughly 15% (5). About 5% of individual s over 65 and 15- 25% over 85 will deve lop
AD (6). In th e next 50 years th e pr eval en ce will a lmos t q uad ruple, meaning that I
in 45 Am ericans will have th e dis ease (4). At pr esent , th e a nnua l incid e nce is
es t ima te d to be 360,000 (4). In th e US, treating AD cos ts 100 billi on do llars a year,
making it the third mos t expe ns ive di sease to treat a fter cancer and heart dis ease
(7) . The di rect a nd tot al cos ts of AD to curre n t and fu ture gene rations are proj ect ed
to reach 536 billi on and 1.75 trillion dollars res pect ively (8).
PSYCH OTIC SYMPTOMS
Some studies ha ve shown th at a pprox ima te ly 30-50% of a ll Alzheimer's patients
will eve n tua lly develop psychoti c fea tures (9, 10). Since a la rge number of AD
patients will develop psychotic sym ptoms some t ime over th e course of their illne ss
proper diagnosis a nd treatment is esse nt ia l (II ). Coope r, e t a i, noted th a t psychotic
sym ptoms were more pr evalent in advance d di sease, but th ey ca n present at an y t im e
during th e di sease course (9). The link between psych otic sym ptoms a nd AD is well
known. Dr. Aloi s Alzh eimer's initial case rep ort described sym ptoms of progressive
mem ory loss, personality changes, delusion al jealousy, paranoia , hall ucina t ions,
ve rba l outbursts, and di sorientation in a 5 1 yea r-old woman (2, 12). Nonpsychot ic
disruptive behaviors su ch as motor restlessn ess, aggressive out bursts, pacing, and
un cooperativeness are oft en mislab el ed as psychotic or a re ass ume d to be re lat ed to
th e underlying psychotic process (13). Thus, in a ny AD patient that suddenl y
develops hallucinations or delusions, other cond it ions need to be ruled out and
include: drug intoxication, drug withdrawal , physical illn ess, depression , an d delir-
ium (3). Much of th e management of Alzheimer's di sease has focu sed on controlling
th ese nonpsychotic di sruptive beh avioral symptom s, in pa rt beca use they a re th e
most di stressin g to ca re give rs a nd a re th e ones most likely to lead to insti tutional-
ization ( 14- 16). Yet , this man agement ofte n lead s to t rial s of antipsychotics in
pat ients with out st r ict ly defined psychotic processes (13).
Delusions, Hallu cinations, and Misi dentifications
The ons et of psychosis in th e AD patient can occur a t a ny tim e, but is more likely
in later stage s of th e di sease (11,17). The specific sym pto ms a re wid e ran gi ng with
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th e most common being delusions, hallucination s, a nd miside ntificat ions (18, 19).
Raskind noted that delusions in AD tend to be "une labo ra te d para noid beliefs based
on th e underlying memory deficit ", th ereby differing from th e "systematized com-
plex delusions of primary thought dis orders" (13). In a re view of s tudies of psychotic
symptoms a mong AD patients, delusions were identified in 10-73% of pat ient s, with
most studies showing a range of 30-38% ( 18). Delusions of th e persecu tory typ e wer e
th e most common, acc oun t ing for 30 -33% of all delusions ( 18-20). A study of 170
patients by Deutsch , e t ai, found fort y-three percent of patien ts had de lusions with
th e following frequencies by typ e: persecutory, 73%; reference, 14.9%; j ealousy, 9.5%;
gra nd iosity, 1.4%; somatic, 1.4% (19).
The second most frequently occurring symptom of psychosis in AD is halluci-
nations. Mu lt ipl e studies have found th at visual hallucin ation s occur mor e oft en th an
auditory or tactile typ es (18 ,19 ,21). Deutsch , e t al, rep orted th at 85% of a ll hall uci-
nations were visual whi le Wragg and ] est e 's review rep ort s a me dian fr equen cy of
13% for auditory hallucinations (18,19). This pattern of greate r vis ua l hallucinat ions
is consisten t with cond it ions like delirium, drug intoxication , drug withdrawal, or
psychosis sec onda ry to a gen eral medi cal cond it ion. Schizophrenia, schizoaffective
di sorder, a nd mo od di sorders with psychotic features typi call y pr esent with auditory
hallucinations. These differences should provide th e clinician with helpful clu es in
th e diagnostic work-up of th e psychotic patient.
A third type of psychotic symptom, misidentification syndromes or mispe rcep-
tions, have been noted in many patients a nd are conceptualized as a form of delusion
(20,22,23) . However, du e their unique charac te r, th ey ha ve been ca tegor ized apart
from delusions and hallueinations (24). Misperceptions result fro m a compromised
ca pacity to organize perceptual informa t ion in th e enviro nme nt. Examples of misi-
dentifications a re th e bel ief that a stranger is in th e house, inability to recog nize
on e 's own reflection, or a beli ef that television shows a re ac tually occurring in th e
house . Burns, et ai, descr ibed a fourth form of misid entification , the erroneous
iden tification of a friend or relative for another person (23) . Mi sid entificat ions have
be en report ed to occur in abou t on e-quarter to on e-third of AD patien ts wit h a
median of 23% (20 ,23,25).
Associated Psychiatric Symptoms
When psychosis is see n with other neuropsych iatri c sym pto ms like dep ression
and agitation, the patient is more likely to be in th e advan ced st ages of th e disease
and more diffi cu lt for the ca re give rs to manage (26) . Levy, et ai , lon gitudinally
exa mined re currence ra tes of neuropsychiat ric symptoms in 181 patients with AD
over a I-yea r period ( 17) . Recurrence rates were 95% for psychosis, 93% for ag itation,
and 85% for depression. Of interest , th e patients that displayed multiple sympto ms
at any point during the study showed greater recurren ce rates of sympto ms during
th e remaining pa rt of the study. Also , if a patient di splayed psycho sis upon initial
evalua t ion, they were more likely to d ispl ay agitation and a n acceler at ed cogni t ive
decline over th e next year. T he patients in the 76-87 yea r group were not ed to have
more psycho t ic symptoms bu t less dep ression a nd agita tion than younge r pati en ts.
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Women were found to di spl ay more neuropsychi at ric sym pto ms than the men. This
study conclude d th at once sympto ms like psychosis, depression, an d agitation begin
that th ey frequently recur and th at varian ces ex ist by sex a nd age ( 17).
Mu ch of th e lit erature re ports th at psych otic sym ptoms are associated with
incr eased cognit ive decline (27-32) . U nde rs ta nd ing th e progression of cognitive
declin e in Alzh eimer's disease a nd its associat ion wit h psych osis is import a n t because
psychotic symptoms a re one of th e prima ry re asons for instit u tion al iza t ion (15,21) .
In support of this, a study of 236 patients by St ern, et a i, foun d t hat patients who
dem on strat ed psychotic symptoms a t th e initial vis it, incr eased thei r re lative risk or
rea ching an institutional ca re rating equivalen t to a nu rsin g home by a factor of 1.5
(33). Lerner, et ai, found th at Alzh eimer's patients with visua l ha llucinations
performed worse on Mini-Mental Sta tus Examinations an d displ ayed more verbal
outbursts, delusions, and paranoid ideat ion than those withou t hallucina tions (29).
In cont ras t to th ese findings, Wragg and]est e, in th eir review of psychosis in AD, cite
seve ra l studies that found delusions were more likely in pa tients wit h high er
cog nit ive scores (18). The expla na t ion give n is th at some level of cognit ion is
necessary for delusions to occ ur (18,32) . T eri , e t a l, fou nd no differe nce in halluci-
nation fr equen cy a t differing levels of cog nitive fun ct ioning (34).
The relationship between pa rticul ar psych oti c sympto ms and associat ed behav-
ior s in Alzh ei mer's patie nt s has also been exa mined (9, 19,29,35). Cooper, et a i,
reported that AD patients with psych osis were twice as likely to be agitat ed (9) .
Lerner, e t a i, found th at visua l hallucin ation s we re pos itive ly associated with
agita t ion a nd paranoid sympto ms (29). Other be hav ioral signs and symptoms
associa te d with visua l hallucination s include d audi tory hallucinat ions, verbal out-
burst s, delusions, a nd paran oid ideation (29) . In a rep ort by Gi lley, e t aI, hallucin a-
tions were associa te d with irritability, di sinhibition , ex trapyramidal symptoms, agi-
tation, a nd delusions (35). Furth er, Deu tch , et a i, concl uded th at th e pr esence or
delu sions and misid entification s might be pr edi cti ve of ph ysical aggression (19) .
Cl early, psychotic symptom s are as socia te d with a wide ra nge of beh avior a l react ions
in Alzh eimer's patients.
Psychosis and Genetics
Recently there has been a focus on th e ge ne t ics of AD, whi ch is a gen et ica lly
het erogen eous disorder associated with 3 det erminative ge nes a nd I suscept ibility
risk ge ne (5). The det erminative ge nes are of th e autosom al dominant type fou nd on
chro mosome s I, 14, and 2 1 are ea rly-onse t form s th at manifest in the 40s a nd 50s,
a nd acco unt for about 5% of all ca ses (5). In 1993, a n a polipoprote in E (APOE)
eps ilon 4 a lle le on chromosome 19 was di scovered to have susce pt ib ility to late-onset
AD by incr easing risk a nd decr ea sin g age of onse t (5,36). The amyloid pr ecursor
prot ein (APP) ge ne is found on chr omosome 2 1 is brok en down to a protein ,
Bet a-amyloid , that is the major cons t itue n t of se nile plaqu es (6). Thus, persons with
Down 's Synd ro me over 40 a lmos t uni versall y have pa t hological fea tures of AD at
auto psy (5) . About 40% of patients with AD have a posi t ive fam ily history for th e
disorder, but th e 50% concordance rate in monozygotic twins studies po ints to
PSYCHOSIS IN ALZHEIMER'S DISEASE 37
environme nta l factors (6,36) . Environmental r isk studies, however, have given varied
results when exa mining th e a re as of head trauma, sex, a nd toxins ( 1,5).
Recent research has focus ed on th e relationship between th e APOE genotype
and psychiatric symptoms to include psychosis (37-4 1). A study by Harwood, et ai,
th at examine d 50 I patients with probabl e or possibl e AD found a n elevated risk for
psych osis a mong th ose with th e eps ilon 4 alle le (37) . Several ot her st ud ies have found
no corre la tion between th e epsilon 4 alle le a nd psychosis (38-40). Sweet, et ai,
exam ined th e dopamine receptor ge ne polymorphism s DRD I, DRD2, DRD 3, and
DRD4 for associa t ions with th e presence of psychosis in AD (42). They found more
psychosis in white patients with DRDI B21B2 homozygosit y (42). Also, psychosis was
more frequent in all AD patients with DRD3 1/101' 2/2 hom ozygosit y (42). This study
conclude d that ge ne t ic va ria t ion in DRD I a nd DRD3 ge nes might mod ify the course
of AD, pr edi sposin g to th e development of psych otic or aggressive symptoms (42) .
NEUROIMAGI TG
Ne uroimaging via compute d tomogr aphy (CT) or magn etic resona nce imaging
(M RI) is not diagn osti c for AD , as AD produces no pathognom oni c cha nges t hat are
see n on conve ntiona l neuroimaging (1,43). However, many expe rts recommend
baselin e imaging to ru le out treatable forms of dem entia. Wh en used , non-contrast
compute d tomography to find a t ro phy or diffuse whi te matter is usuall y sufficient
(43) . leuroa na to rnica l corre la te s of seve r ity of illn ess a nd present a tion of be havioral
symptoms have lon g been known in AD . Zubenko, et ai, showed th a t psychot ic AD
patients had increased den sities of seni le plaques in th e pro subiculum of the
hippocampus and incr eased densities of neurofibri llary tangles in th e middle fron tal
corte x when compa re d to non-psych otic AD patients a t a uto psy (44). Thei r findings
a re interesting to not e as chro nic idiopathic psych osis of ea rl ie r life is accompanied
by decr eased blood flow and glucose metabolism in th e frontal cortex a long with ce ll
loss in t he hippocampus (44) .
Posit ron em ission tomography (PET) a nd sing le e mission compute d tom ogr a-
phy (SPECT) allow for visualization of brain a bnormalit ies via new approaches to
convent ional im aging ( 1,44) . In th e future PET and SPECT may a llow for early
pr edi ction of whi ch patients will develop psychosis. In ge neral, AD ca uses red uced
perfusion or metabolism in th e region of th e ternporo-parieto-occipital j unct ion as
visualized by SPECT or PET ( 1,45). AD patients show reduced perfusion a nd
met abolism in th e cort ica l associa t ion areas that spa res th e ba sal ga ng lia, th al a mu s,
ce re be llum, a nd primary corte x (3) . Organic psychosis a nd schizophrenia have been
hypothesized to be th e result of temporal , pa ri et al , a nd front al lobe dysfun ct ion ;
howeve r, th e neuroa na tomic substrat e for hallucin ations a nd delu sion s is unknown
at this time ( 10). Yet , many studies have found that delusions cor re la te with
temporal and fronta l lobe dysfuncti on on PET a nd SPECT (46). Kotrl a, e t a i,
examine d th e hypothesis th at psychosis in patients with AD was associated with
ce re bra l dysfunction in both th e frontal and th e parietal lobes, since vir tua lly all AD
patients have temporal lobe pathology ( 10). They found that delu sional patients had
hypoperfusion of the left fronta l lobe while hallucina ting pa tients had hypoperfusion
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in th e parietal lobes. This study conclude d that psychotic pat ients with AD had
ce re bra l blood flow deficits significan t ly different fro m nonpsych otic patients with
AD (10) . Thus, AD may provide a model for investigation of th e manifesta t ions of th e
ce re bra l dysfunction that produces psychosis (10).
MA TAGEMEf\'T
If th ere is mini mal potential danger to t he patien t or ot hers, reassurance and
di stracti on is th e t reat ment of choice for psychot ic AD pa tien ts (47) . If agitation or
violen t beh avior is pr esent a nd places the pat ient or caregivers at risk for harm,
ph a rmacologic treatment a long with one-on-one care is ofte n req ui red. In som e cas es
restraints may be required but ongo ing usc must be j ust ified. The number on e goal
is patient and st aff sa fe ty a nd comfort. Agitation , which ofte n accompanies psychosis,
may be du e to an undiagnosed condit ion such as pain , a nx iety, hunge r, cons t ipation,
or fear of aba ndo nme nt. Treatm ent here should focus on reassurance, attending to
unmet needs a nd correct ing th e underlying condit ion with ca re ful medi ca l eva lua -
tion (47,48).
Neuroleptics
The primary man agem ent of psychosis in Alzhe ime r 's d isease ha s t rad it iona lly
reli ed up on neuroleptic medi cation s th at have lon g been used to target delusion s,
hallucin ations, and ag ita t ion ( 14, 15). The usc of neu rol ept ics in th e elderly popula-
tion is complex because adverse effec ts arc com mo n a nd se nsit ivity to drug-drug
interactions is incr eas ed (49). In thi s population th e adve rse effects of grea test
con cern include orthostatic hypot ention, delirium, ex t ra-pyram idal symptoms (EPS),
tardive dyskinesia, urinary ret ention , a nd gla uco ma. Sunde rla nd noted that elderly
dem ented patients may be more se ns it ive to th e adve rse effects of neurolep tic drugs
and may require lower doses than non-dem ent ed controls ( I I) . Of particular not e is
that th e risk for tardive dyskinesia ('I'D) is 50% in th ose 65 years or older eve n with
shor t-te rm use (49) . Traditionall y, low doses of high-pot en cy ag ents like haloperidol
have been th e initial drugs of choice (50, 51). Halop eridol may ca use parkinsonism,
making monitoring for bradykin esia, rigidity, a nd sia lorrhea necessa ry (52) . A
randomized, pla cebo-controlled dose-comparison trial of haloperidol for psychosis
a nd disruptive behaviors was conducte d recently by Devan and (53). T his study
indicated a favorable th erapeutic profile for doses of 2-3 rug/day of haloperidol, but
a subgroup of patients developed EPS (53). The use of low-pot en cy neuroleptics
should ge ne ra lly be avoide d du e to th ei r anti-ch olinergic effects ( 15). Also, patients
with Alzh eim er 's di sea se are a t high risk for fall s or may have chronic obst ru cti ve
lung disease, urinary ret ention , cons tipa tion, or other con ditions in whi ch low-
pot en cy agents a rc contraindica te d ( 14,15).
The development of newer medi cations suc h as risperidon e and olan zapine,
hav e made the drug of initial choice for psychosis a n a rea of deb at e (54). Medicat ions
such as risperidone hav e gained favor in th e treatment of schizophrenia a nd ot her
psychotic disorders largely because of safer side -effec t pr ofiles. Risp eridone has
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received support from some ge ria t r ic clinicians who re port effec t iveness at very low
dos es (0.5-2.0 mg/d ay) (47,55 ). Several stud ies have shown risperidon e to be effec-
tive in reducing psych oti c symptoms a mo ng dem ented patients (25,49,56). Kat z, et
ai , exa mined 625 institutionalized patients with dem entia (73% wit h AD) and
significa n t psychosis or beh avioral sympto ms in orde r to eva lua te t he efficacy and
sa fe ty of risp eridone in thi s population (56) . The pat ients were randomized in a
double-bl ind , placeb o-cont roll ed fash ion to placebo, low-dose (0.5 mg/day), medium-
dose ( I mg/day), or high-dose (2 mg/day) risperido ne for 12 weeks (56) . The study
concl ude d th at risp eridon e significa n t ly improved sym ptoms of psychosis in severe
dem entia with I rug/d ay being an ap propriate dose for most patients (56). With
regards to sa fety, th e fre que ncy of EPS was not significan tly great er than placebo for
those receiving I rug/d ay of risp eridon e (56) . C lozapine may prove usefu l for tho se
patients se ns it ive to EPS, but du e to its high cos t, wee kly to biweekly blood
monitoring, and risk for ag ra nulocytosis, it s use may be limited in this popula tion
(55). Tariot reviewed reports of clozapine use in psych oti c dem ent ed patie nts and
found a mixed pict ure in terms of efficacy a nd side effec ts with som e report s showing
a reducti on in psych osis a nd agita t ion while ot he rs showing no ben efit (25) . T he
elde rly a re more susce pt ible to bruisin g, seda t ion, hypoten t ion, confus ion, and other
a n t i-cho line rg ic effec ts of clozapine . Most of t he published lit era ture for the use of
clozapine in thi s population is based on ope n tria ls, chart reviews, and case reports.
Thus, th ere is a lack of controlled tri al s.
Ol an zapine a nd quetiapine a re newer drugs th at show sim ilar efficacy to
conve nt iona l neuroleptics a nd do not require blood monitoring (47) . O la nza pine a nd
quetiapine a re not significantly different from placebo in regards to EPS pr ofiles a nd
ha ve lower risk of tardive dysken esia. Olanzapine has been shown to be generally
sa fe in schizophre nic populations but may be acco mpa nied by mi ld sedat ion, som e
a nti-cho line rg ic effec ts, di zzin ess and weight gai n (57) . Quetiapine has been shown
to ca use no cha nges in hematological or ECG profi les , required no blood monitoring,
a nd di spl ays low EPS profiles (58). However, que tiapin e demonstrat es substa n t ia l
hist amin ic recep tor blockade with resulting dizziness, postura l hypot en sion, somno-
len ce, a nd weight ga in in some patient s (59). An in terim analysis at 12 weeks of an
ongo ing one yea r, ope n trial of qu etiapine in 151 elde rly pat ien ts wit h dement ia (75
patients with AD ) and mixed beh avioral problem s, including psychosis, was recently
performed (60). Patients received 25 mg to 800 mg/day of qu etiapine (median
dose = 100 mg/day) with 6% of patients showing EPS. This study concl uded th a t
qu etiapine was well tolerat ed and associa te d with improvem ent in elde rly pat ient s
with psychotic disorders (60) .
Implem entation a nd dosing of a n t i-psyc ho tics agents is com plex. In general,
non-pharmacologic a lte rnat ives should be attempte d first du e to large num bers of
pot ential side -e ffec ts of a nti-psyc ho tics . Gen erall y, side -e ffec t profiles dictat e the
cho ice of agent a nd ca n be minimized by usin g th e lowest effect ive dose (47). Dosing
should ge ne ra lly be st arted at about Ij{ to 1j2 th e usual adult dose a nd risks versus
ben efit s mu st be reassessed on a n ongoing basis. For exa mple with haloperidol, a
sta r t ing dos e of I mg /day with gradual, upward dos e titration is recommended (53).
Use of anticholinergic age nts should be avoided. Som e authors sugges t it may be
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more beneficial to sche d ule medi cation in a n t icipa t ion of be havior rather than
reacting to symptoms with as need ed medi cation orders (5 1). In ot her words, identify
sp ecific times of day or ac t ivit ies that pr ecipitat e ce r tain unwant ed behavior and
medi cat e about on e hour prior to this time (25) . Most commo nly, this wou ld be at
night to help fost er slee p and treat a ny behavior al pr obl ems th at oft en peak at that
time (47) .
Alternative Agents
A wide variety of other ag ents have been used with some succe ss, including
lithium, bet a-blockers, se lect ive serotoni n reuptake in hibitors (SSRI's) , trazodon e,
bu spiron e, benzodiazapines, a nd a nti -convulsants (47,50,5 1). Ge nerally, th ese agents
have been used to t reat agitation or aggress ion ra ther than used to treat psychosis
per se . For behavioral con t rol, th e use of t razodone seems promising in severa l
stud ies ( I I). Trazod on e give n a t bedtime reduces nigh tt ime ag itation, whil e lower
doses during th e day help with daytime ag itat ion (52) . Preli mina ry dat a suggest
SSRI's may help a llev ia te ag itat ion (47) . Ant i-convulsants may be indicat ed for
mildly agita te d patien ts who do not res po nd to an ti-psychotic medi cation (47).
Althou gh an t i-co nvulsan ts have fewer side -effects, blood monitoring is required .
Ben zod iazepines have been show n to cont ro l behavioral problems bett er th a n
placebo but not as we ll as a nt i-psyc ho tics (47). Benzod iazepines arc oft en give n in
conj unc t ion with a nt i-psyc ho t ics but sho uld be used with ca u tion in Alzh eimer's
patients. Generall y, th e use of low-dose, sh ort-acting agen ts with no active metab-
olites (i.e.-oxazepam or loraz epam) are th e initial d ru gs of cho ice . Unfortunat ely,
side effec ts suc h as a taxia, confus ion, a nd seda t ion may place th e pat ient at risk for
falls . No ne of th e a lte rnative agen ts have been foun d to target psychosis but may be
helpful in treating associa te d agita t ion in a ppropria te cases (49) .
C um mings describes th e th ree ph armacologic treatments in use at pr esent in
th e t reatment of AD: di sease-mod ifyin g agents, agen ts to manage symptoms of
cog nit ive deficit s, a nd psychotropic agents for beh avioral dis turbances (52) . Both th e
clinical lit erature and th e public have em braced vitamin E, est roge n, cholinest erase
inhibitors and gingko biloba as possibl e di sease-m odi fying agents or t rea tmen ts for
cog nitive deficits (52) . The pr esent st ra tegy is to treat mild-t o-m od erately affect ed
patients with vitamin E and a choline ste rase inhibitor (i.e.- don ep ezil ) . The us e of
cho lines te rase inhibitors appears to slow th e ra te of cognit ive decline in some
patients a nd may help to reduce hallucin ation s and delusions (52) . P rincipa l limita-
t ions of these age nts include th eir expense a nd ina bili ty to stop th e course of th e
disease. In later stages of th e di sease, psych ot ro pic agents arc usually necessary and
prolon ga tion of th e illn ess with vitamin E may no longer be a th erapeutic goal (52).
Post-m en op au sal wome n on es trogen develop AD less often, and estrogen given to
wom en who already have AD show reduced cognit ive effects (52) . No studies to dat e
show wh ether or not those given es troge n are less likely to deve lop psychotic
symptoms. There is some evide nce th at individual s ad ministe re d non-s teroidal
a n t i-infla mma to ry drugs (NSAIDS) demonstrat e lower incid en ce of AD, but little
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prosp ective data is available (52). No evide nce to date has suggest ed th e use of
NSAIDS prevents th e development of psychosis in AD patients.
Non-pharmacologic Approaches
The efficacy of nonpharmacologic interven tio ns In th e t rea t men t of psycho sis
remains to be es tablishe d and in many inst ances will ha ve only limited ben efit
(53, 6 1,62) . Yet , so me so urces st ress th at behavioral t herapies are important in th e
man agement of AD as th ey may reduce th e occurre nce of psych ot ic symptoms in
patients and decr ease st ress in ca regivers (I 4, 15). Typicall y, specific behavioral
techniques a re organized a ro und th ree ce ntral th emes: I) mod ification of th e
ph ysica l enviro nme nt to minimize ex t rane ous st im uli a nd maximize pat ient dignity
a nd sa fe ty; 2) training of ca regivers to com m unica te effect ively with AD pati ents;
a nd 3) pr ovision of emotional support , com m unity resour ce information , a nd respite
ac t ivit ies for ca regive rs . Modifyin g th e enviro nment may be qu ite simple (26) . For
exa m ple, it is oft en help ful to a r ra nge the home in a n or derly an d syst ematic way
wit h not es to remind th e patient wh ere things are (26) . Good lighting, carefu l
placement of mirrors, a nd ab sence of tel evision s or radi os can help re d uce delusions
a nd misid entifications (20). Sin ce visio n a nd hearing impairmen t often contribut e to
problems for AD pat ients it is important to ens ure the patient 's glasses and hearing
a ids are in good orde r. Assisting non -profession a l ca regivers is vital in th e t rea t ment
of AD , as non -profession al s provid e 80% of overall care (26). T eaching fami ly
members to comm unica te effec t ive ly wit h the AD pat ient ca n a me liora te some of th e
fru stration pat ients may evo ke . Refer ring family members to th e local chapter of th e
[at ion a l Alzh eimer's Disease & Rela ted Disorders Association ca n im prove th ei r
access to com m unity resources a nd ove ra ll qualit y of care (26,52).
If the patient reaches th e point whe re institutionali za t ion becomes necessary,
specia l ca re units a re oft en ava ilable (20,63) . These uni ts provide a safe, non -
threatening enviro nme nt in whi ch ir relevan t st im uli are reduced (20). In recen t
years suc h unit s have become incr easin gly avai lable a nd may slow th e decline of
func t iona l ca pacity . A recen t study of 1228 resi dents in 48 facilities with special ca re
unit s demon strat ed no stat ist ica lly significa nt di fferences in speed of decline from
tradition al unit s; however, th e authors concl uded that th ese units might pr ovid e
unmeasured ben efits to families a nd resid ents by improving overall q uality of
life (63) .
CONCLUSIONS
The associa t ion bet ween psych ot ic sym pto ms an d Alzheime r's d isease is well
know n, and th ese sym ptoms are di st ressing to pa ti ents, ca re give rs, and clinicians. It
is also know n th at de lusions, hallucination s, a nd miside n t ifica t ions occur commonly
among AD pa t ie nts a nd a re associate d with significant morbidity. Controversy
remains as to whether or no t psychot ic sym ptoms lead to a more ra pid cognit ive
declin e, but most researc he rs agree th at psych osis is pos itively associa ted with
agita t ion a nd aggression (9, 19,29,35) .
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C urre nt man agement of psych osis ce nters on use of a nt i-psychotic medi cation ,
behavioral th erapy, and family ed ucat ion ( 14, 15,20,5 0,5 1). T here is a pau city of
scientific lit erature on th e nonpharmacologic a pproaches to th e management of
psychosis in AD and th eir overall efficacy is yet to be proven (53,62). W ith regards to
ph armacologic management, th e use a nd development of newe r med ica t ions with
fewer side -e ffec ts appears promisin g (47) . At th e pr esent ti me the litera ture lacks a
number of con t rolled studies on th e a typica l an t i-psychotics in AD patient s, but it
appears t ha t more studies are for thco ming. The effects of spec ia l ca re uni ts on
func t ional outco me in AD is a n a rea th at requires more investigation (63). C ur re nt
Research is now usin g func t iona l neuroimaging to examin e AD, but neuroan at omic
corre la tes of psychosis in AD remain largely unknown (3,10). Articl es addressin g
possible differen ces bet ween psychoti c sym pto ms in t he fam ilia l forms a nd th e
suscept ibility form of AD were not located in thi s review. The hop e is that more will
be di scovered about possibl e ge ne tic co rre la tes to th e neu ropsychi at ric symptoms of
AD in th e near future. It is a ppa rent fro m this review th a t m uch wor k remains in th e
examina tion of th e di sease th at Alzhe im er describ ed as, "a pecu liar di sease of th e
ce re bra l cor tex" (2).
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